22130 Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML.

This activity can be accessed using the following URL: www.peerview.com/HJG

This activity is supported through educational grants from Bristol Meyers Squibb

 

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of AML.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML)
  • Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines
  • Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT
Additional information

Contact

Name: 
Mallory Ahern
Phone Number: 
+1 (914) 737-6528
Email: 
mallory.ahern@peerview.com
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
05/18/2022
Course expires: 
05/19/2023
Cost:
$0.00

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
James M. Foran, MD, FRCPC
Associate Professor of Oncology
Chair, Acute Leukemia & Myeloid Neoplasm Disease Group, Mayo Clinic Cancer Center
Jacksonville, Florida

James M. Foran, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gamida Cell and Servier Laboratories.

Co-Chair & Presenter
Uma Borate, MD, MS
Associate Professor of Medicine
Department of Internal Medicine
Division of Hematology
The Ohio State University
The James Comprehensive Cancer Center
Columbus, Ohio

Uma Borate, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Astellas Pharma Inc.; Genentech, Inc.; Incyte Corporation; and Novartis Pharmaceuticals Corporation.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

 

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.